FDA approves USGI Medical’s pivotal study of the POSE2.0 procedure for primary obesityThe FDA has approved an USGI Medical’s Investigational Device Exemption application to conduct a pivotal study of its POSE2.0...
USGI Medical completes Pilot Study of the POSE2.0 incisionless weight loss procedureThe FDA has acknowledged the successful completion of a pilot study of USGI Medical’s incisionless, endoscopic gastroplasty procedure,...
GLP-1s associated with higher risk of major depression, increased risk for anxiety and an elevated risk for suicidal behaviour1 day ago